Small
Molecule Anti-infective Drug Market, by Product Type (Antibiotics (B
Lactam, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulphonamides,
and Others), Antifungal ( Azoles, Echinocandins, Polyenes, and Others),
Antivirals (Nucleoside Reverse Transcriptase Inhibitors, Non-nucleoside Reverse
Transcriptase Inhibitors, and Others), and Others (Anthelminthic and
Antiprotozoal), by Indication (Pneumonia, MRSA Infections, MSSA Infections,
Sinusitis, Tuberculosis, Dermatophytosis, Aspergillosis, Candidiasis,
Hepatitis, HIV Infection, Respiratory Tract Infection, Urinary Tract Infection,
and Others), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies,
and Online Pharmacies), and by Region (North America, Europe, Asia Pacific,
Latin America, Middle East, and Africa) - Global Industry Insights, Trends,
Outlook, and Opportunity Analysis, 2019 – 2026
Small molecule anti-infective
drugs are used for the treatment of various infectious diseases such as
Methicillin-resistant Staphylococcus aureus (MRSA) infections,
Methicillin-Susceptible Staphylococcus aureus (MSSA) infections, sinusitis,
cellulitis, pneumonia, tuberculosis, aspergilosis, and hepatitis.
Anti-infective drugs have the capability to eliminate and suppress infections
that are caused by various bacteria and viruses.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2655
Small Molecule Anti-infective
Drug Market Drivers
Increasing approval of new drugs
is expected to drive growth of the global small molecule anti-infective drug
market. For instance, in April 2019, the U.S. Food and Drug Administration
(FDA) announced the approval of Dovato (dolutegravir and lamivudine), which is
used for the treatment of HIV-1 infection in adults. It is manufactured by ViiV
Healthcare.
Furthermore, in August 2018,
Tetraphase Pharmaceuticals received the U.S. Food and Drug Administration
approval for its new drug, Xerava containing Eravacycline, which is used for
the treatment of complicated intra-abdominal infections (CIAI).
Small Molecule Anti-infective
Drug Market Restraints
Increasing severe side effect of
drugs is the major restraining factor of anti-infective drug market, it is
expected to the hamper the small molecule anti-infective drug market growth.
For instance, NBC news report in December 2018, U.S Food and drug
administration sends warning letters to Fluroquinonolone antibiotics because
U.S FDA found that Fluroquinolones antibiotic can increase the occurrence of serious
events of rupture in the main artery of the body. These ruptures called as the
aortic dissections.
Small Molecule Anti-infective
Drug Market Regional Analysis
On the basis of region, the
global small molecule anti-infective drug market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/small-molecule-anti-infective-drug-market-2655
North America is expected to hold
dominant position in the small molecule anti-infective drugs market, owing to
new product launches of small molecule anti-infective drugs. For instance, in
November 2018, Xellia Pharmaceuticals launched its new product, Vancomycine
Hydrochloride for injection, in the U.S market.
Furthermore, Asia Pacific is also
projected to witness significant growth in the global small molecule
anti-infective drugs market, owing to increasing collaboration activities among
key players. For instance, in April 2018, Entasis Therapeutics Holdings Inc.
collaborated with the Zai Lab Limited. This collaboration facilitated phase III
clinical trial for a fixed-dose combination of ETX2514 and sulbactam. This
combination is intended for the treatment of multidrug-resistant infections
caused by Acinetobacter baumannii bacteria. The study started in April 2019 and
is expected to complete in July 2020.
Key players operating in the
global small molecule anti-infective market include, Merck & Co., Inc.,
AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG,
Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithKline plc. (GSK),and Allergan plc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2655
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment